Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease

<div>Trend of the mean number of tender joints, swollen joints, and disease activity score on 28 joints-C-reactive protein (DAS28-CRP) at the start of canakinumab (baseline) and at the three subsequent follow-up visits. Error bars refer to one standard deviation.</div>

Mediators of Inflammation

fig2

Figure 2

Figure 2: Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease 